Life Sciences Policy

CRA’s policy team provides analysis and insights into global, regional and national policy issues affecting patients, the healthcare system, and the life sciences industry. CRA has a reputation for independence and rigor, benefiting from long standing relationships with most leading life sciences organizations as well as national governments and the European Commission and industry associations. Our specialist team has provided unique policy oversight for the past 20 years delivering high quality, robust analysis in a compelling fashion that is accessible to the target audience, whomever it may be.

Our focus areas


  • 01
    Adapting ICER to transformative medicines
    Our client is a global pharma company and is interested to understand the implications of the 2019/2020 updates to the ICER Value Assessment Framework...
    View engagement
  • 02
    Assessed likely policy response in major markets to COVID-19
    Identified risks to pricing and market access in global markets for related and non-related therapeutic areas CRA Approach Developed a framework that captures...
    View engagement
  • 03
    Characterising the benefits of personalised medicines
    Our client was seeking to develop an evidence base to support the contribution of personalised medicines to patients, healthcare systems and society more...
    View engagement

Subscribe to receive our latest Insights.